Belite Bio (BLTE) Long-Term Investments (2025)
Belite Bio's (BLTE) quarterly Long-Term Investments came in at $280.2 million in Q4 2025.
Belite Bio (BLTE) Long-Term Investments (2025) Analysis & Trends
Belite Bio's Long-Term Investments history runs 1 years deep, the most recent figure standing at $280.2 million for Q4 2025.
- On a quarterly basis, Long-Term Investments changed N/A year-over-year to $280.2 million in Q4 2025; TTM through Dec 2025 was $280.2 million, a N/A change from a year earlier, with the FY2025 full-year figure at $280.2 million, changed N/A from the prior year.
- Long-Term Investments steadied at $280.2 million in Q4 2025 per BLTE's latest filing.
- Across five years, Long-Term Investments topped out at $280.2 million in Q4 2025 and bottomed at $280.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 505,194.89 |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 5.75 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 9.79 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 22.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 280.17 Mn |